Ensign Peak Advisors
MAZE

Ensign Peak Advisors’s Maze Therapeutics MAZE Stock Holding History

Ensign Peak Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.03M Sell
101,644
-84,150
-45% -$2.21M 0.01% 658
2026
Q1 		$5.55M Hold
185,794
– – 0.01% 510
2025
Q4 		$7.7M Buy
185,794
+115,129
+163% +$3.96M 0.01% 454
2025
Q3 		$1.83M Buy
70,665
+52,126
+281% +$880K ﹤0.01% 824
2025
Q2 		$227K Buy
+18,539
New +$193K ﹤0.01% 1674

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Ensign Peak Advisors's MAZE Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Maze Therapeutics (MAZE) stake by 45% in Q2 2026, selling an estimated $2.21M and leaving 101,644 shares worth $3.03M. The position accounts for 0.01% of the portfolio, ranked #658.

Ensign Peak Advisors first reported a position in MAZE in Q2 2025 and has held it in 5 quarters since. The position peaked at $7.7M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Ensign Peak Advisors held 101,644 shares of Maze Therapeutics worth $3.03M as of Q2 2026.
  • Ensign Peak Advisors sold 84,150 Maze Therapeutics shares in Q2 2026, an estimated $2.21M.
  • Maze Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #658 holding.
  • Ensign Peak Advisors first reported a position in Maze Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Ensign Peak Advisors's Maze Therapeutics position peaked at $7.7M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.